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In the last decade, mass spectrometry has been employed by more and more researchers for
identifying the proteins in a macromolecular complex as well as for defining the surfaces of
their binding interfaces. This characterization of protein–protein interfaces usually involves at
least one of several different methodologies in addition to the actual mass spectrometry. For
example, limited proteolysis is often used as a first step in defining regions of a protein that
are protected from proteolysis when the protein of interest is part of a macromolecular
complex. Other techniques used in conjunction with mass spectrometry for determining
regions of a protein involved in protein–protein interactions include chemical modification,
such as covalent cross-linking, acetylation of lysines, hydrogen-deuterium exchange, or other
forms of modification. In this report, both limited proteolysis and chemical modification were
combined with several mass spectrometric techniques in efforts to define the protein surface
on the HIV core protein, p24, recognized by two different monoclonal human antibodies that
were isolated from HIV patients. One of these antibodies, 1571, strongly inhibits the CD4 T
cell proliferative response to a known epitope (PEVIPMFSALSEGATP), while the other
antibody, 241-D, does not inhibit as strongly. The epitopes for both of these antibodies were
determined to be discontinuous and localized to the N-terminus of p24. Interestingly, the
epitope recognized by the strongly inhibiting antibody, 1571, completely overlaps the T cell
epitope PEVIPMFSALSEGATP, while the antibody 241-D binds to a region adjacent to the
region of p24 recognized by the antibody 1571. These results suggest that, possibly due to
epitope competition, antibodies produced during HIV infection can negatively affect CD4 T
cell-mediated immunity against the virus. (J Am Soc Mass Spectrom 2006, 17, 1560–1569)
© 2006 American Society for Mass SpectrometryConventional structural biology techniques havebeen the most powerful avenues for determiningthe molecular details of protein structure and pro-
tein–protein interactions. Understanding protein structure
and the protein–protein interactions of the cell at a basic
level (i.e., determination of their molecular architectures,
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another) is imperative for understanding how the disrup-
tion of a single element can result in human disease. Mass
spectrometry (MS) is showing tremendous potential for
both identification of protein complexes and elucidation of
protein structure, in particular for proteins that are not
amenable to classical structural techniques. The advan-
tages of MS sensitivity, low sample consumption, and the
ability to analyze heterogeneous mixtures can overcome
the obstacles that hamper other structural methods. Using
MS, in conjunction with limited proteolysis and chemical
modification, the structure of a protein or a protein–
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distances and changes in solvent accessibility.
One class of protein–protein interaction that can be
probed using mass spectrometry is that of antibody–:
antigen interactions (epitope mapping). Several labora-
tories have developed mass spectrometric methods for
determining the antigenic determinants on a protein
using antibody immobilization, proteolytic digestion,
differential chemical modification of amino acid resi-
dues, and mass spectrometry [1–3]. In the system de-
scribed here, we examined two antigenic determinants
on the human immunodeficiency virus (HIV) core pro-
tein p24 and demonstrated the ability to define quater-
nary protein structures using mass spectrometry.
The HIV/acquired immunodeficiency syndrome
(AIDS) global pandemic, of course, is a tremendous
burden on human health. Figures from the World
Health Organization’s December 2005 AIDS epidemic
update concluded that 40 million people are infected
with HIV world-wide, with 5 million new cases and 3
million deaths in 2005 alone (ISBN 92 9 173439 X).
Hence, intense research has centered on the recognition
of HIV by the immune system with much effort di-
rected towards understanding how the virus is able to
evade the immune system and ultimately result in AIDS
(for review see [4 – 6]. Understanding these interactions
between the immune system and HIV could possibly
lead to more effective treatments. Furthermore, eluci-
dation of the molecular details of the immune system’s
response to HIV infection could also lead to the devel-
opment of preventative measures such as vaccines (for
review see [7, 8]. In fact, much has been learned about
the antigenic proteins of HIV and the immune response
triggered by the detection of these proteins in the
circulation. Antibodies that are capable of neutralizing a
broad spectrum of HIV isolates have been documented
[9 –11], but the presence of these antibodies in HIV 
patients is rare, possibly in part because the epitopes
these antibodies recognize are fleetingly exposed to the
immune system (e.g., a rare conformation of the viral
envelope proteins during membrane fusion with the
target cell) [11]. The CD4 helper T cell response is
another important element of the immune response, in
particular for clearing the virus from the infected indi-
vidual or preventing progression of the infection to
AIDS (reviewed in [12]). Unfortunately, strong helper T
cell responses are also uncommon in the majority of
HIV-infected subjects. The reason behind the lack of
strong helper T cell response to HIV is an area of
continuing research. Likely, the suppression of the
CD4 T cell response is in large part due to the targeted
infection of these cells by HIV [13–16], but recent
studies have shown that the immune system’s own
antibodies may also serve to inhibit the CD4 T cell
response by binding the antigen from which the epitope
displayed by the major histocompatibility complex
(MHC) would be derived and somehow block recogni-
tion by the T cell [17–22]. Nevertheless, much hope
exists in the field for the development of a multipleantigen vaccine that will induce an immune response
that will protect against HIV infection by eliciting a
strong T cell response as well as inducing production of
broadly neutralizing antibodies.
One HIV protein that is a target for vaccine devel-
opment is HIV p24 [7, 8, 23–26]. HIV-p24 is the major
component of the HIV core and is one of the mature
protein products that results from proteolysis of the 55
kD HIV gag polyprotein. p24 is of clinical interest
because strong CD4 T cell responses against p24 were
found to correlate with control of viremia and with lack
of progression to AIDS [27]. However, this antigen also
elicits high titers of antibodies in the course of HIV
infection. Indeed, the presence of antibodies in the
serum that recognize p24 was one of the first clinical
tests developed to diagnose HIV infection [28, 29].
Antibodies against the conserved regions of this protein
also maintain high affinity binding despite the high
mutation rate of the virus [30]. Nevertheless, anti-p24
antibodies do not mediate any known antiviral func-
tions. Rather, such high affinity antibodies may inter-
fere with antigen processing and presentation for class
II MHC-restricted CD4 T cells. To examine this issue,
CD4 T cell proliferation in response to p24 was eval-
uated in the presence of human monoclonal antibodies
(mAbs) specific for this particular antigen. The present
study demonstrates that two mAbs from HIV patients
against p24 have distinct inhibitory effects on CD4 T
cell proliferation in response to p24. One mAb strongly
blocks the T cell proliferation, while the second mAb
does not display as strong an inhibitory effect. One
possible reason is that the first mAb binds to regions on
p24 that are close to or overlap with the T cell epitope,
preventing the epitope from being properly presented
by the class II MHC to the CD4 T cells. In contrast, the
second mAb may recognize a region of p24 that is
distinct from the T cell epitope. In efforts to test this
hypothesis, the epitopes on p24 that these mAbs recog-
nize were determined.
Experimental
Materials
Recombinant p24 was purchased from Austral Biologi-
cals (San Ramon, CA) or from Protein Science (Meriden,
CT). Cyanogen bromide activated sepharose 4B was a
product from GE Healthcare Biosciences Corp. (Piscat-
away, NJ). Modified trypsin was a product of Promega
(Madison, WI) and GluC a product of Roche (Indianap-
olis, IN). BS3 was purchased from Pierce (Rockford, IL)
and acetic anhydride, D6-acetic anhydride, antihuman
IgG Fc made in goat, and all other chemicals were from
Sigma (St. Louis, MO).
Antibody Production and Purification
Antibody expressing B-cells were isolated from HIVindividuals and immortalized with Epstein-Barr virus,
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antibodies purified as described by Gorny et al. [31].
T Cell Inhibition Studies
A CD4 T cell clone specific for p24 (AC-25) was exam-
ined in this study; the generation and characterization
of this clone were reported previously [32]. The clone was
human leukocyte antigen-DR-1 (HLA-DR1) restricted
as described [32], and its minimal epitope was mapped
to PEVIPMFSALSEGATP. T cell proliferative responses
to p24 were evaluated in the presence or absence of
mAbs in 3H-thymidine incorporation assays as de-
scribed previously [18]. Autologous Epstein Barr virus-
transformed B cells were used as antigen presenting
cells.
Bead Preparation and Antibody Immobilization
Antihuman IgG Fc antibodies were immobilized onto
cyanogen bromide activated sepharose 4B beads fol-
lowing essentially the manufacturer’s recommended
protocol and methods previously established [33].
Briefly, beads were swelled in water and then exten-
sively washed with 1 mM HCl. After equilibration in 50
mM phosphate pH 8.4, 500 mM NaCl, 5 mg of antihu-
man Fc antibodies per mL of resin were incubated for
1 h at 25 °C with gentle mixing. Unreacted sites on the
activated beads were then quenched by the addition of
100 mM tris pH 8.0. Following another series of washes,
20 g of either mAbs, 1571, or 241-D, were captured
onto the antihuman IgG Fc beads. The resulting anti-
body complex was then covalently cross-linked by incu-
bating the beads for 1 h with 10 mM BS3. After quenching
with 100 mM Tris pH 8.0 and re-equilibration with buffer,
the beads could be used immediately or could be stored
for up to 1 wk at 4 °C.
Epitope Extraction
Epitope extraction assays were performed essentially as
described previously [1–3, 34]. Briefly, p24 was digested
to completion with either trypsin or GluC. The resulting
digest was then incubated with either the mAb 1571 or
the mAb 241-D coated beads. The beads were then
washed and analyzed by spotting the resin directly onto
the MALDI target to determine if any peptides were
retained on the beads.
Epitope Excision
Epitope excision assays were conducted as described by
Parker and Tomer [1, 2, 35]. In short, intact p24 was
bound to either the mAb 1571 or the mAb 241-D coated
beads followed by varying degrees of proteolysis with
either trypsin or GluC. After a series of washes to
remove unbound peptide fragments, the beads were
spotted directly onto MALDI targets and analyzed by
mass spectrometry.Differential Acetylation Studies
Acetylation of primary amines of p24 (11 lysines and
the N-terminal amine) were performed either in the
absence of any antibody (control set) or in the presence
of either the mAb 1571 or the mAb 241-D essentially as
described by Hochleitner et al. [36]. Briefly, 2 g of
recombinant p24 in 20 L of 100 mM phosphate pH 8.0
(4 M) was treated with 5 mM acetic anhydride for 30
min at room temperature. pH was monitored by pH
strip every 5 to 10 min and adjusted upward by the
addition of aliquots of 5 M NaOH as needed to main-
tain a pH 7.0. At the end of the reaction, an equal
volume of 1 M Tris pH 8.0 was added to quench any
remaining unreacted acetic anhydride. The p24 was
then purified by HPLC on an HP 1100 capillary HPLC
system removing salts as well as dissociating the p24
from the mAbs. Fractions containing p24, as assayed by
MALDI-MS, were pooled and lyophilized. After lyoph-
ilization, p24 was resuspended in 20 L of 100 mM
phosphate pH 8.0, 2 M D6-acetic anhydride, and al-
lowed to react for 1 h at room temperature. p24 samples
were then desalted using C4 ZipTips from Millipore
(Billerica, MA) and the manufacturer’s recommended
protocol. Acetylated p24 was then digested with trypsin
or GluC (pH 4) and MALDI-MS and ESI-MS (see below)
were performed on the resulting peptides. Candidate
acetylated peptides were identified by first comparing
the ions present in each of the acetylated p24 digests
that were not present in the control p24 digest. This list
of ions was then compared with the theoretical proteo-
lytic digests (up to three missed cleavages) of p24. The
ions that corresponded in mass to a predicted proteo-
lytic fragment of p24 plus the mass of one or more
acetylations were then analyzed by either MALDI-
MS/MS or nano LC-ESI-MS/MS to confirm their iden-
tities. Monoisotopic peak heights were used to calculate
ratios of H3/D3 for the control p24 samples and for the
mAb bound p24 samples. By comparing these ratios,
the effects that antibody binding has on lysine reactivity
and, presumably, lysine surface accessibility were
quantitated. Duplicate MS analyses were performed on
independent acetylation experiments (at least two) to
determine the ratios of acetylation to D3-acetylation.
MALDI Mass Spectrometry
Samples (0.5 L) were spotted onto a 100 sample
stainless steel MALDI plate and mixed on target with 0.5
L of a saturated solution of -cyano-hydroxycinnamic
acid in 45:45:10 (vol:vol:vol) water:ethanol:formic acid.
Mass spectrometric analyses were then performed on
an Applied Biosystems DE-STR MALDI-TOF mass
spectrometer (Foster City, CA) in the positive ion and
either linear or reflector modes. The MS spectra were
calibrated externally using a mixture of standard pep-
tides. Data were acquired using an accelerating voltage
of 25,000 V; grid percentage of 80%; and a delay time of
300 nanoseconds for linear mode analyses and an
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and delay time of 125 nanoseconds for reflector mode
analyses. For MS/MS analyses, samples were spotted,
0.3 L, onto a 192 sample stainless steel MALDI plate
and mixed on target with 0.3 L of 33% saturated
-cyano-hydroxycinnamic acid. MS/MS were then per-
formed on an Applied Biosystems 4700 Proteomics
Analyzer in the positive ion and reflector modes. The
MS/MS calibrated externally using the fragment ions of
the angiotensin I M  H ion (m/z 1296.68) with instru-
ment settings of 1000 V for the collision energy and
argon as the collision gas with a recharge threshold set
at 1.0  107 torr.
NanoLC ESI Mass Spectrometry
For ESI-MS analyses, samples were introduced into a
Q-TOf Ultima mass spectrometer (Waters/Micromass,
Altrincham, UK) using flow injection from a pressur-
ized bomb at a flow rate of 300 nL/min. Mass
spectrometer settings for MS analyses included a capil-
lary voltage of 3.8 kV, cone voltage of 90 V, collision
energy of 10 V, RF setting of 110 V, and a cone gas flow
of 50 L/h. NanoLC-ESI-MS/MS analyses were per-
formed using an Agilent 1100 nanoLC system on-line
with either a Q-TOf Ultima mass spectrometer or Agi-
lent MDS XCT Ultra ion trap mass spectrometer (Agi-
lent Technologies, Waldbrunn, Germany). Briefly, 8 L
of 100 nM acetylated p24 digest were loaded onto a
PepMap C18 column (75 m  150 mm, Dionex/LC
Packings, The Netherlands) followed by a 15 min wash
of 5% acetonitrile, 0.1% formic acid. Peptides were
eluted by applying linear gradient from 5% acetonitrile,
0.1% formic acid to 45% acetonitrile, 0.1% formic acid to
the column over 45 min. This was followed by a 5 min
gradient from 45% acetonitrile, 0.1% formic acid to 95%
acetonitrile, a 0.1% formic acid and then a 10 min hold
at 95% acetonitrile, 0.1% formic acid. MS/MS data were
acquired using a data dependent acquisition format.
Mass spectrometer settings for MS/MS analyses on the
Q-TOf Global Ultima were capillary voltage of 3.8 kV;
cone voltage of 90 V; RF setting of 110 V; and a cone gas
flow of 50 L/h. Collision energies were applied based
on the mass and the charge state of the candidate ions.
The Agilent MDS XCT Ultra ion trap mass spectrometer
with the chip-cube option was used in the positive ion,
ultrascan mode, and included settings of an ionization
potential of 1.7 kV and an ICC smart target (number of
ions in the trap before scan out) of 100,000 or 500
milliseconds of accumulation. MS/MS analyses were
performed using automated switching with a prefer-
ence for doubly charged ions and a threshold of 5000
counts and a 1.3 V fragmentation amplitude.
Results and Discussion
Because antibodies produced during HIV infection
have been shown to have inhibitory effects on the
presentation of HIV antigens to MHC class II-restrictedCD4  T cells [18, 19], we investigated the effect of
human p24-specific mAbs on CD4 T cell recognition of
HIV gag antigen p24. Two anti-p24 mAbs (241-D and
1571) were tested and compared with an irrelevant
mAb specific for gp120 (654-D). All of these mAbs were
generated from cells of chronically HIV-infected sub-
jects. Of the two anti-p24 mAbs tested, mAb 1571
completely blocked p24-mediated proliferation of the
CD4  T cells (Figure 1). The inhibitory effect was
observed at each p24 concentration tested. MAb 241-D
also reduces p24-mediated proliferation, but only at
lower p24 concentrations (Figure 1). In agreement with
previously published data [19], anti-gp120 mAb 654-D
showed no inhibitory effect (Figure 1). Hence, anti-p24
mAbs 1571 and 241-D displayed distinct effects on
CD4 T cell proliferation in response to the p24 antigen.
In efforts to identify the regions of p24 recognized by
the CD4 T cell inhibiting mAb 1571 and the less
inhibiting mAb 241-D, a mass spectrometry-based ap-
proach was employed. Specifically, the purified mAbs
were immobilized onto sepharose beads and either the
intact p24 antigen or an enzymatic digest of p24 was
captured. Both the mAb 1571 and the mAb 241-D
coated beads were capable of precipitating the intact
p24 antigen as was determined by MALDI-MS analyses
(Figure 2a and b). Conversely, under the conditions
used in the experiments, neither of the mAb beads was
able to precipitate any peptides from the digested p24
antigen (Figure 3a and b). Consistent with these data,
both mAbs failed to react with any overlapping syn-
thetic 20-mer peptides spanning the entire p24 protein
sequence (data not shown). These results suggest that
while both mAbs are able to specifically recognize p24,
the epitopes recognized by these antibodies are either
discontinuous or linear but conformation dependant
(e.g., epitope is part of a tight turn in the protein, but
Figure 1. Proliferative responses of p24-specific CD4 T cell clone
AC-25 in the presence of human mAbs to p24 or gp120. T cell
response was assessed with varying p24 concentrations (4–120
nanomolar), while the mAbs were tested at a constant amount of
67 nanomolar. Recombinant p24 was first incubated with mAbs
for 1 h at 37 °C. The p24/mAb mixtures were then added to
irradiated APCs. After an overnight incubation, the T cells were
added and cultured for 3 d. 3H-thymidine uptake was assessed in
the last 18 h of culture. The background response of AC-25 to
APCs with no p24 was 408 cpm. Data from one of two indepen-
dent experiments are shown.exists as random coil as a digested peptide). The possi-
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are linear and contain proteolytic site(s) such that when
they are treated with protease, the epitope is destroyed.
To test this possibility, the p24–mAb complex immobi-
lized on beads was subjected to varying degrees of
proteolysis with both trypsin and GluC. Interestingly,
very few if any peptides are derived from the mAbs
themselves. This is believed to be the result of several
factors including disulfide bonding and possible inher-
ent resistance imparted by some level of glycosylation,
as well as intramolecular cross-links between lysine
residues formed during the BS3 treatment. These cross-
Figure 2. MALDI-MS showing the singly, doubly, and triply
charged states of HIV p24 analyzed directly from 241-D mAb
coated beads (a) and 1571 mAb coated beads (b).
Figure 3. Epitope extraction studies indicate no
to the 1571 mAb (a) or the 241-D mAb (b). MA
bound to the 1571 mAb shows multiple peptides
cleavages) bound to the mAb coated beads (c). M
bound to the 241-D mAb shows a single peptide f
remains bound to the mAb coated beads (d).links both inhibit tryptic digestion at these lysines as
well as prevent release of lysine-containing, cross-
linked peptides that are formed by digestion at arginine
(trypsin), or aspartate and glutamate (GluC). Extended
digestion times (overnight) resulted in no peptides
remaining bound to the mAb coated beads (data not
shown). These data are interpreted as evidence that
both mAbs recognize either linear but conformation
dependent or discontinuous epitopes because several
examples exist in the literature where a site of proteol-
ysis in a linear epitope is protected from enzymatic
digest by antibody binding and is retained on the
antibody resin even after long digestion times [1, 2,
36 –38]. Furthermore, limited proteolysis (1 h digestion
with trypsin at room temperature and a 1:200 enzyme:
antigen ratio) followed by MS analyses showed the
presence of several proteolytic fragments of p24 re-
maining bound to the beads coated with the mAb 1571
and one large p24 fragment remaining bound to the
mAb 241-D coated beads (Figure 3c and d).
In the case of the mAb 1571, several ions were
observed remaining bound to the antibody coated resin
(Figure 3c). Singly protonated ions were observed at m/z
7227, 7629, 12470, 15774, and 17080. These ions match
closely in mass to the tryptic peptides T4–T6, residues
31–97 (Mtheor  7224.5, [Mtheor are all predicted average
masses of singly protonated species] T1–T4, residues
1–70 [residues are numbered from proline 1 of p24,
which corresponds to residue 149 of the gag polypro-
tein; Mtheor are all calculated average masses of singly-
protonated species] (Mtheor  7626.9), T2–T9, residues
19–132 (Mtheor  12,466.2), T1–T11, residues 1–143
(Mtheor 15771.2), and T2–16, residues 19–170 (Mtheor
17077.6). Other ions were also observed but are multi-
ply charged species of T1-T11, T2-T9 and T2-T16. All of
the peptides observed originate from the N-terminus of
the protein with the residues 31–70 represented in all of
ides from the completely trypsinized p24 bound
S spectrum of epitope excision studies of p24
the N-terminus of p24 remain (all with missed
I-MS spectrum of epitope excision studies of p24
the N-terminus of p24, T5-T12 (residues 71–154),pept
LDI-M
from
ALD
rom
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the minimal peptide length that is still capable of
binding to the mAb 1571. This fragment of p24 com-
prises all of -helices 2 and 3, a significant portion of
-helix 4, as well as the loop regions between these
-helices.
Similarly, as seen if Figure 3d, when p24 complexed
with the mAb 241-D was digested using conditions that
resulted in limited proteolysis, an ion was observed at
approximately m/z 9437, closely matching in mass to
T5-T12, residues 71–154 (Mtheor  9435.8). This peptide
is also from the N-terminal domain of p24 and contains
the C-terminal portion of -helix 4, -helices 5–7 as well
as the loops between these helices. T5–T12 was the only
peptide observed under the conditions used, suggesting
that residues 71–154 is the minimal peptide that main-
tains high affinity binding with the mAb 241-D.
The results obtained for these limited proteolysis
experiments allowed for the rough determination of the
regions of p24 recognized by each of these antibodies.
Moreover, in addition to trypsin, other proteases in-
cluding ArgC, chymotrypsin, GluC, and LysC were
used for both the epitope excision and epitope extrac-
tion experiments. As was seen when trypsin was used,
no peptides were retained on the antibodies during
epitope extraction, and large fragments from the N-
terminus of p24 remained bound during epitope exci-
sion assays (data not shown). Due to the multiple
fragments observed with in the epitope excision assay
with the mAb 1571 and their overlap with the residues
identified as remaining bound to the mAb 241-D, as
well as the differing phenotype of the two antibodies, a
finer characterization of the epitopes was needed to
explain the differing biological manifestations of the
Figure 4. Sequence of HIV p24 with residues observed by mass
spectrometry underlined. (a) Shows sequence observed using a
combination of ESI- and MALDI-mass spectrometric analyses of
tryptic and GluC digests of unmodified p24 while (b) details
sequence coverage of peracetylated p24 using the same biochem-
ical and mass spectrometric techniques.two antibodies. Therefore, to define the epitopes recog-nized by each of these antibodies with greater resolu-
tion, a differential chemical modification strategy was
adopted [36, 37]. Briefly, p24 was acetylated (mass gain
of 42 Da) at its lysines when complexed with each of the
antibodies, dissociated from the antibodies, and then
deutero-acetylated with D6-acetic anhydride (mass gain
45 Da). These acetylated p24 samples were digested
with proteolytic enzymes and both MALDI- and
ESI-MS were used to identify acetylated peptides based
on the presence of ions that were multiples of 42 Da
heavier than the predicted peptide masses from theo-
retical digests of p24 (Figure 4a and b for sequence
coverage maps). These ions were further scrutinized by
MS/MS analyses. The presence of an acetylated lysine
(or the protein’s N-terminus) was determined based
upon the resulting b- and y-series ions as well as by the
presence of the 143.1 Da acetylated lysine immonium
ion (Figure 5a). The ratio of acetylation to D3-acetylation
was determined using peak intensities of the monoiso-
topic peaks observed in ESI-MS data (Figure 5b). These
ratios were then used to assess lysine reactivity in the
free and antibody bound p24 and the change in lysine
reactivity determined by comparing ratios obtained in
the presence of each of the antibodies with the ratio
obtained in the absence of any antibody (Table 1).
Significance of these values were determined using a
t-test with a P value .05.
Figure 5. (a) ESI-MS spectrum of the m/z 1029.6 and m/z 1031.1
ions corresponding to the doubly protonated, acetylated or D3-
acetylated tryptic fragment T1 of p24 in the absence of antibody.
The areas under these peaks were measured and solvent accessi-
bility determined.(b) MALDI-MS/MS spectrum of the singly
protonated ion of the N-terminal tryptic peptide of p24 (m/z
2058.8) acetylated on the N-terminal proline with b- and y-series
ions labeled.
peptide is shown in green (c) and (d).
Ratios and errors could not be calculated because of the absence of
D3-acetylation.
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several lysines on p24 were found to have altered
reactivity including 30Lys, 131Lys, and 140Lys. Upon first
inspection, the protection of 131Lys and 140Lys does not
appear to correlate well with the observation that
residues 31–70 may be the minimal binding unit for this
mAb. When mapped to the X-ray crystallographic
structure (PDB ID 1E6J), however, clearly these lysine
residues are in relatively close proximity to residues
31–70 in three-dimensional space (Figure 6a). 30Lys is, of
course, immediately N-terminal to the proposed mini-
mal fragment of p24 for mAb 1571 recognition. The
protection of 131Lys by the mAb 1571 binding is not
surprising because the side-chain of 131Lys is oriented
towards the proposed minimal binding unit, specifi-
cally -helix 2. In the crystal structure of p24, the 131Lys
side chain is in a position that would suggest the
possibility of hydrogen bonds between its amine hydro-
gens and the backbone carbonyl oxygen of 44Ser as well
as the carboxylate oxygens of the side chain of 45Asp.
The protection of 140Lys by the mAb 1571 is not as
readily explained. The side chain of this lysine appears
to be directed primarily towards the solvent in the
crystal structure of p24 and is not immediately proxi-
mal to the putative minimal binding unit of p24, resi-
d (d) models of p24 (PDB 1E6J) with the regions
24 (residues 31–70) that remains bound to 1571
hlighted in yellow (a) and (c), and the region of
d beads is shown in blue (b) and (d). Lysine
(all panels) while the PEVIPMFSALSEGATPFigure 6. Ribbon (a) and (b), and space filling (c) an
affected by mAb binding highlighted. The region of p
mAb coated beads in the epitope excision assay is hig
p24 (residues 71–154) retained on 241-D mAb coate
residues affected by mAb biding are shown in redTable 1. Lysine reactivities of p24
(p24-1571)/p24 (p24-241D)/p24
N-terminus 0.97/0.05 0.98/0.07
25Lysa 1.37 1.41
30Lys 0.67/0.04 1.06/0.05
70Lys 0.97/0.09 0.76/0.11
131Lys 0 /0.02 0.41/0.02
140Lys 0.73/0.02 0.58/0.03
170Lys 0.89/0.10 1.01/0.09
182Lys 1.02/0.22 1.06/0.19
227Lysb 1 1
Lysines, as well as the N-terminus, were modified as described in the
methods where the p24 was first modified under mild conditions with
acetic anhydride, desalted, and then subjected to conditions that should
allow for any remaining unmodified lysines to be deutero-acetylated by
D6-acetic anhydride. The acetylation:D3-acetylation ratio was then calcu-
lated for each of the observed lysines for p24 alone, in the presence of the
1571 mAb, or the 241-D mAb. The changes in reactivity in the presence of
each of the antibodies were determined by dividing the values. Values
significantly greater than 1.0 indicate an increase in reactivity3, suggesting
an increase in exposure, significantly less than 1.0 indicate a decrease in
reactivity, suggesting protection, and values that do not differ significantly
from 1.0 suggest no change in reactivity of the lysine upon antibody
binding. At least two independent mass spectrometric measurements
weremade on at least two independent acetylation reactions and standard
deviations are shown.
3[significance determined by t-test with P values  0.05.]
aSingle measurement.
b
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from the residues involved in the mAb:antigen inter-
face, this lysine side chain is still occluded by antibody
binding. Furthermore, while it is postulated that resi-
dues 31–70 may be the minimal fragment of p24 recog-
nized by the mAb 1571, it is noteworthy that larger
fragments containing 131Lys and 140Lys were also in the
epitope extraction assays. This indicates that, even
though residues 31–70 bind the mAb 1571, an even
larger fragment of p24 may make up the complete
surface that is recognized by the mAb 1571.
Similarly, differential acetylation studies were per-
formed on p24 in the presence of the less inhibiting
mAb 241-D. In these experiments, several lysines of p24
were found to have altered reactivity when p24 was
bound to the mAb 241-D. 70Lys, 131Lys, and 140Lys all
exhibited decreased reactivity in the presence of this
mAb, correlating well with the epitope excision assay
where residues 71–154 were retained by beads coated
with the mAb 241-D (Figure 6b). 70Lys is immediately
N-terminal of the T5-T12 peptide observed in the
epitope excision assay while both 131Lys and 140Lys are
contained within this fragment.
Interestingly, several peptides, both tryptic (exclud-
ing those where the cut site was destroyed by acetyla-
tion) and those generated by GluC digestion, of p24 that
were readily observed when p24 was not acetylated,
became difficult to detect by both ESI- and MALDI-MS
when the protein was acetylated (Figure 4a and b). In
fact, when p24 was digested with trypsin or GluC and
analyzed by a combination of MALDI- and LC-ESI-MS,
93% of the sequence of p24, including all lysine resi-
dues, was observed when the protein was not acety-
lated, but when the protein was peracetylated, sequence
coverage dropped to 68% with only 8 of 11 lysine
residues observed. Possibly, the acetylation of the basic
lysine residues decreases the ionization efficiency of the
peptides or that the acetylation decreases the polarity
sufficiently that the peptides are lost to surfaces during
subsequent sample handling due to increased hydro-
phobicity. For example, peptides in the C-terminal
portion of p24 containing 158Lys, 199Lys, and 202Lys,
while observed when p24 is not acetylated, are not
observed when p24 is acetylated. Presumably, the lack
of sequence coverage in these areas upon acetylation is
not detrimental because the epitope excision studies
demonstrate that only the N-terminal portion of p24 is
recognized by the mAbs 1571 and 241-D. Another
important example of this effect that does have bearing
on the epitope determination of the mAbs 1571 and
241-D is the GluC peptide S1, residues 1–29, which was
readily observed when p24 was not acetylated, but only
observed once for each mAb when p24 was acetylated.
This peptide contains both the N-terminal amine and
25Lys. This peptide demonstrated an increased acetyla-
tion to D3-acetylation ratio when p24 was complexed to
the antibodies. It is assumed that this increase in
acetylation was through 25Lys as the tryptic fragment
T1, residues 1–18, and showed no obvious change in theratio of acetylation to D3-acetylation at the N-terminal
amine. Hence, apparently upon mAb binding, the re-
gion of the protein near 25Lys may become more solvent
exposed, but the significance of this increased exposure
is not known.
The differential acetylation studies provided infor-
mation about the reactivity of the lysines of p24, and
some further refinement of the epitopes on p24 recog-
nized by the T-cell inhibiting mAb 1571 and the less
inhibiting mAb 241-D was achieved. The epitope exci-
sion experiments yielded large fragments of p24 that
comprised large surfaces from multiple faces of the
protein. The differential lysine acetylation studies al-
lowed for refinement of these surfaces to a single face
for each of the antibodies. In Figure 6a, residues 31–70
of p24 are highlighted. These residues are found both
on the “front” of the protein as well as the “back” of the
molecule. The lysines that had altered reactivity upon
mAb 1571 binding are all on the same side of the
protein and narrowed the region of p24 thought to be
recognized by mAb 1571.
Similarly, a large fragment of p24, residues 71–154,
was found to remain bound to mAb 241-D coated
beads. This fragment also comprised multiple faces of
p24. The differential lysine acetylation studies enabled
further refinement of the mAb 241-D binding surface as
well. In Figure 6b the residues 71–154 and the lysines
affected by mAb 241-D binding are highlighted. The
epitopes that these two mAbs recognize appear to be
adjacent with some probable overlap because both
mAbs protect 131Lys and 140Lys from acetylation.
Interestingly, when the epitope recognized by the
p24-specific CD4 T cell line is highlighted along with
the epitope mapped for the 1571 mAb (Figure 6c) it is
apparent that these epitopes overlap entirely. Because
of the direct overlap of the mAb and T cell epitopes,
simple competition between the antibody and the T cell
for the epitope could be the mechanism by which the
1571 mAb interferes with the T cell proliferative re-
sponse. On the other hand, the mAb 241-D appears to
bind to a surface of p24 that is adjacent to the epitope
recognized by the AC-25 CD4 T cell clone used in this
study (Figure 6d), possibly resulting in the partial
inhibition of the T-cell proliferative response by this
antibody. It is more likely, however, that the antibody
241-D functions by an indirect mechanism similar to
that as has recently been shown for some HIV gp120-
specific antibodies which inhibit the gp120 specific
CD4 T cell helper response is by interfering with
antigen processing in the antigen-presenting cells [17–
20, 22]. In the case of the gp120-specific antibodies, the
antibody binding to gp120 confers some resistance to
proteolytic enzymes in the endolysosomes such that
peptide epitopes are not efficiently released and pre-
sented by the antigen-presenting cells [17, 22]. Possibly
the antibodies 1571 and 241-D also bind to the N-
terminal domain of p24 in such a way that this domain
is stabilized and becomes more resistant to endosomal
and lysosomal enzymes. The results further imply that
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under the acidic conditions found in the lysosomes.
Further studies are necessary to test the effects of these
antibodies on the presentation of other CD4 T cell
epitopes to elucidate each of the multiple possible
mechanisms by which these antibodies inhibit the
CD4 T cell response against p24.
Conclusions
In this study, mass spectrometry, in conjunction with
limited proteolysis and chemical modification, was
used to define the regions of a protein involved in a
protein–protein interface. Specifically, the protein–
protein interfaces between the HIV protein p24 and
two different human monoclonal antibodies were de-
termined. The determination of the regions of p24
recognized by each of these antibodies is clinically
important because of the potential effects that each of
these antibodies may have in vivo. If a relatively
conserved region of a p24 protein is determined to be
highly antigenic for eliciting responses from CD4 T
cells, it could be considered as a lead epitope for vaccine
development. However, if this antigenic region elicits
competing antibody responses that inhibit the T cell
response, then vaccines targeted to this particular re-
gion might not be as effective. In the case of T cell
epitope PEVIPMFSALSEGATP, this epitope completely
overlaps with that recognized by the mAb 1571 and its
T cell recognition is strongly blocked by the mAb 1571.
Nevertheless, the recognition of this T cell epitope is
also affected, albeit weakly, by the mAb 241-D, even
though the epitope of this mAb is located in an adjacent
nonoverlapping region. The mechanisms by which the
mAb 241-D exerts its inhibitory effects remain to be
determined, but could be a function of an indirect
disruption of antigen processing and presentation as
has been observed for other systems. Further character-
ization is warranted for these two antibodies, as well as
for additional antibodies to other regions of p24. These
studies should include not only epitope mapping, but
also biophysical characterization of the interactions
between the antibodies and p24 including binding
affinities and thermal stabilities of the complexes.
The mass spectrometry-based approaches described
here were an effective method for determining the pro-
tein–protein interactions between p24 and the monoclonal
antibodies 1571 and 241-D. The limited proteolysis exper-
iments were particularly useful for this antibody–antigen
interaction, allowing for quick, albeit low-resolution, de-
termination of the epitopes recognized by each antibody.
The chemical modification experiments also showed util-
ity as these experiments allowed for the finer localization
of the binding interfaces between the two different anti-
bodies and p24. These differential acetylation experi-
ments, however, do have some limitations. They are
labor intensive and require extensive optimization.
Moreover, in these studies, it was observed that several
peptides of p24, while readily observed in the absenceof acetylation, became difficult to observe when the
protein was acetylated. The underlying cause of this
effect is not known, but it could be due to the loss of the
basic nature of the lysine side chain after acetylation
and, hence, loss of ionization efficiency. Another possi-
bility is that a loss of polarity upon acetylation increases
the hydrophobicity of these peptides enough that they
are lost during subsequent sample handling. Neverthe-
less, other stable chemical modification techniques,
such as protein oxidative surface mapping [39 – 43], or
succinylation of lysines [44, 45] show great promise for
mapping protein–protein interactions and will be ap-
plied to this as well as other antibody–antigen systems.
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